Background-Interleukin 1 (IL-1 ) and its natural antagonist have been implicated in the pathogenesis of inflammatory bowel disease (IBD). Both cytokines influence bone formation. IL-1 stimulates osteoclast activity while interleukin 1 receptor antagonist (IL-1ra) enhances bone formation. Aims-To determine whether the decreased bone mass in IBD is related to gene polymorphisms coding for IL-1 and IL-1ra, and thus identify patients with an increased risk. Cytokines influence bone remodelling by regulating diVerentiation as well as the activity of osteoclasts and osteoblasts. A key proinflammatory cytokine interleukin 1 (IL-1 ) stimulates osteoclast development and activity, 2 and was found to decrease bone collagen and noncollagen protein synthesis.
Inflammatory bowel diseases (IBD)-Crohn's disease (CD) and ulcerative colitis (UC)-are associated with decreased bone mineral density and an increased prevalence of osteoporosis. 1 The pathogenesis of this increased bone loss is not yet fully understood. Risk factors for reduced bone mass in patients with IBD may include the causes of idiopathic osteoporosis, as well as specific factors related to the inflammatory process.
Cytokines influence bone remodelling by regulating diVerentiation as well as the activity of osteoclasts and osteoblasts. A key proinflammatory cytokine interleukin 1 (IL-1 ) stimulates osteoclast development and activity, 2 and was found to decrease bone collagen and noncollagen protein synthesis. 3 The naturally occurring antagonist of IL-1 , the interleukin 1 receptor antagonist (IL-1ra), stimulates bone formation and decreases the number of osteoclasts on the endocortical surfaces. 4 Moreover, greater spinal bone loss was observed among premenopausal women with higher stimulated production of IL-1 . 5 Spontaneous secretion of IL-1 by cultured peripheral blood mononuclear cells was significantly higher in osteoporotic patients compared with healthy subjects. 6 As in high turnover osteoporosis, enhanced circulating levels of IL-1 have been reported in patients with IBD. 7 The altered production and mucosal ratio of IL-1 and IL-1ra is strongly suggested to be a pathogenic factor in IBD. [8] [9] [10] Increased production of IL-1 was implicated as a possible reason for increased bone loss in IBD. 11 Family, twin, and epidemiological studies indicate that genetic factors play an important role in determining bone mass. [12] [13] [14] Assessment of bone turnover markers suggests a genetic influence in the regulation of bone metabolism. 15 Although there is evidence that the genotype influences both peak bone mass and the rate of bone loss, no overall susceptibility genes for osteoporosis have yet been identified. [16] [17] [18] [19] [20] [21] The inconsistencies of candidate gene studies are due to the multifactorial regulation of bone mineral density: a polygenic predisposition is modified by environmental and lifestyle factors.
As members of the IL-1 family play an important role in the regulation of bone formation, genes involved in the control of their activity provide other candidate loci for susceptibility to increased bone loss. Indeed, allelic variations at the IL-1 receptor antagonist gene (IL1RN) were found to be associated with early postmenopausal bone loss at the spine. 22 Further evidence on the genetic control of bone loss comes from studies of Cox and colleagues. 23 These authors found a linkage between the severe forms of rheumatoid arthritis characterised by bone erosions and the IL1 gene cluster, while this linkage was not present in the non-erosive form of the disease. 23 As to the actual influence of allelic variations on cytokine levels, production of both IL-1 and IL-1ra protein are related to the TaqI and AvaI genetic polymorphisms in the IL-1 (IL1B) and the variable number of tandem repeats (VNTR) polymorphism in the IL1RN gene. [24] [25] [26] An allelic combination of these polymorphisms in the IL1B gene was found to be associated with the disease course in CD. Among CD patients with non-fistulising disease, homozygotes for allele 1 at the TaqI site were more frequently carriers of allele 2 at the AvaI polymorphic site while this was not found in healthy controls or in patients with fistulising CD. 27 Based on previous observations, this study aimed to answer the question whether genetic polymorphisms in the IL1B and IL1RN genes influence bone mass in patients with IBD compared with healthy controls. Genomic DNA was extracted from EDTA anticoagulated peripheral blood according to the standard proteinase-K digestion and phenol-chloroform extraction method. Two biallelic restriction fragment length polymorphisms (RFLP) at positions −511 and +3953 of the IL1B gene and a penta-allelic VNTR polymorphism in the IL1RN gene were determined according to previously described methods. 27 30-32 Summarised conditions are given in table 2.
Materials and methods

PATIENTS
BONE MINERAL DENSITOMETRY
Bone mineral densitometry was performed by dual x ray absorptiometry at the left femoral neck, lumbar spine (L 2 -L 4 ), and the distal third of the non-dominant radius using a Hologic QDR 4500C instrument (Hologic Inc., Waltham, Massachusetts, USA). The longitudinal precision of measurements on a Hologic spine phantom has a coeYcient of variation of 0.35%. Data were obtained for absolute areal bone density (g/cm 2 ) and were also expressed as the number of SDs below or above the age and sex standardised average (Z scores). According to the recommendations of the WHO, T score values were used (the number 27 33 In IBD patients, the MANOVA test showed significant diVerences between bone mineral density (BMD) values of carriers and noncarriers of allele 2 at the AvaI polymorphic site (IL1B-511*2). Carriers of allele IL1B-511*2 had significantly lower BMD values at the lumbar spine (p=0.03) and at the femoral neck (p=0.007) while at the radius the diVerence did not reach statistical significance (overall MANOVA p=0.048) (table 3). These findings were also present when sex and age standardised Z scores were compared (lumbar spine p=0.03; femoral neck p=0.003; overall MANOVA p=0.03) (table 3). The relative risk of low bone mass (osteopenia or osteoporosis) at the femoral neck was also higher for carriers of allele IL1B-511*2. Among the 23 patients with low bone mass detected at this site, only three were non-carriers of the IL1B-511*2 allele (OR 3.63; 95% CI 0.95-13.93). However, this phenomenon could not be observed at the lumbar spine (OR 1.47; 95% CI 0.46-4.68) or at the radius (OR 1.5; 95% CI 0. 36-6.26) .
No There were no significant diVerences between the groups of carriers and non-carriers of allele IL1B-511*2 in terms of age, age at disease onset, body mass index, ratio of patients with CD and UC, or occurrence of corticosteroid therapy in their anamnesis (table 1) . Similarly, we found no significant diVerences in male/female ratios between carriers and noncarriers of the IL1B-511*2 allele. However, when analysing male and female IBD patients separately, in men there was a significant association between lower Z scores and the presence of allele IL1B-511*2 both at the lumbar spine (p=0.01) and at the femoral neck (p=0.038) while in women there was no association at the lumbar spine but only at the femoral neck. Moreover, after correction for multiple comparisons, the diVerence found at the femoral neck in women was no longer significant.
There was no association in IBD patients between Z scores and the presence of allele 2 at the VNTR gene polymorphism in the IL1RN gene (IL1RN*2) or the presence of allele 2 at the TaqI gene polymorphism in the IL1B (table  4) . Similarly, in HC, no association was found between bone mineral density and carriership of allele 2 at any of the investigated polymorphic sites (carriers v non-carriers of allele IL1B-511*2: lumbar spine 1.00 (0.02) v 1.03 (0.02); femoral neck 0.84 (0.03) v 0.89 (0.03); radius 0.71 (0.01) v 0.71 (0.02)). No significant association was found between the −511 and +3954 gene polymorphisms in our HC while the frequency of the IL1B-511*2 allele was higher in the IBD than in the control population (0.44% v 0.31%).
Discussion
The pathogenesis of reduced bone mineral density in IBD is not fully understood. Patients with corticosteroid treatment, small bowel disease or intestinal resection, or a longstanding or extensive disease have been suggested to be at a higher risk of bone loss. However, there is no consensus in diVerent studies as to which factor is significant in the evolution of decreased bone mass. 11 34-36 Moreover, a high prevalence of low bone mineral density was found in patients with newly diagnosed CD and among IBD patients with a low risk of metabolic bone disease. 11 These results raise the possibility that other factors, present already before the onset of the disease, contribute to the low bone mass and enhanced bone loss in IBD patients.
In this study we have found that the presence of the IL1B-511*2 allele was associated with significantly lower Z scores and a higher risk of osteopenia and osteoporosis in IBD patients. This allele has previously been related to increased in vitro production of IL-1 by mononuclear cells. 25 Elevated levels of IL-1 and/or an imbalance between IL-1 and IL-1ra production could result in increased bone loss. IL-1 was described as enhancing bone resorption by increasing the number and activity of osteoclasts while having no eVect on bone formation. Animal studies have also suggested that IL-1ra treatment decreased the activity and number of osteoclasts on endocortical surfaces. 4 Previous studies in IBD have shown increased bone resorption rates while levels of bone formation markers were similar to those of healthy individuals. 11 37 Thus the lower bone mass of IBD patients can be partly explained by elevated IL-1 levels and increased IL-1 / IL-1ra ratio observed in these diseases.
Similar to our findings, the study of Keen and colleagues 22 suggested the importance of IL1 genes in determining bone mass. In their population of early postmenopausal women, an association was found between the presence of the IL1RN*2 allele and reduced bone loss at the spine. This allele has previously been related to increased production of IL-1ra. 24 Thus in patients carrying the IL1RN*2 allele, IL-1 could induce a smaller biological response when competing for binding to IL-1 receptors. However, in the study of Keen et al, an association was only seen between the IL1RN polymorphisms and the rate of bone loss, not with actual Z scores, whereas in the present study the IL1B-511 polymorphism was found to influence bone mass in IBD. These diVerences may be due to the diVerent ages of the study groups, to the presence of IBD, or to the diVerent end point of the studies.
As there is evidence that IL1B genotype influences the course of IBD, 27 32 these results suggest that the inflammatory process alters regulation of bone resorption, as previously described. Our earlier studies found a higher frequency of the IL1B-511*2 allele among UC patients whose leading symptom was diarrhoea than among those presenting with spontaneous rectal bleeding. 27 Therefore, we propose that a specific disease course related to or manifested as alterations in the nature of intestinal absorption-such as an accelerated passage or greatly increased intestinal permeability causing dysregulated absorption-may be associated with a higher extent of bone loss. For instance, a recently published study has found that intestinal permeability is also a useful predictor of relapse in patients with CD and faecal calprotectin in both CD and UC. 38 Genetic variations in the IL1B gene have been linked to several other chronic multifactorial diseases such as adult periodontal disease, 39 40 insulin dependent diabetes mellitus, 41 and schizophrenia. 42 Thus we could hypothesise that the IL1B gene, by controlling the production of IL-1 , influences the severity and course of diVerent diseases. Additional genetic, environmental, and lifestyle factors or infections would determine if any of these diseases develops. Although we could not fully confirm the lack of association between the IL1B-511 polymorphism and BMD in the general population because of the smaller number of individuals in the HC group in this study, our results suggest that the underlying bowel disease resulting in long term upregulated IL-1 production may be necessary to induce bone loss. A recently published study has also shown an example of interaction of the IL-1 gene cluster and additional host factors towards progression to disease. A higher frequency of the IL1B-511*2 allele among Helicobacter pylori infected relatives of gastric cancer patients with low acid secretion was found but not among those not infected with H pylori. 43 Moreover, the study also found almost total linkage disequilibrium between the IL1B polymorphisms at positions −511 and −31, this latter being a TATA box polymorphism markedly aVecting DNA-protein interactions in vitro.
Our results suggest that sex may be an important modifying factor in IBD. Male sex was reported to be an independent risk factor for osteoporosis in earlier studies. 35 It is currently accepted that oestrogen plays a key role in the regulation of bone turnover in both sexes. [44] [45] [46] Recent studies have demonstrated that oestrogens reduce expression of signalling type IL-1 receptor (IL-1RI) in osteoclasts while it increases expression of decoy type IL-1 receptor (IL-1RII), together decreasing IL-1 bioresponsiveness of these cells. 47 This regulatory eVect of oestrogen was similar in cells from both male and female donors. In contrast, steady state IL-1RII/IL-1RI ratios in osteoclast-like cells of men were found to be lower than those of early postmenopausal women, suggesting that similar IL-1 levels may have a stronger bone resorptive eVect in men than in women.
In this study the association between the genotype of the AvaI gene polymorphism and bone mass in IBD patients was strongest at the femoral neck. This is in agreement with other studies reporting a greater prevalence of reduced hip BMD in IBD compared with the frequency of vertebral or forearm osteopenia.
11 34 48 This would further confirm that the pathogenesis of bone loss in IBD is diVerent from the clearly steroid induced bone disease, which aVects vertebrae to a greater extent.
Although several general and IBD related osteoporosis risk factors are suspected to contribute to the increased bone loss in IBD, results on the extent of their roles are controversial and are not applicable to predicting osteopenia in the long term at the time of diagnosis of the disease. We have shown that carriers of the IL1B-511*2 allele have a higher risk of presenting with low bone mass in IBD. These results may extend our knowledge regarding the pathogenesis of low bone mass in IBD patients. Furthermore, screening for the AvaI gene polymorphism in the IL1B gene could contribute towards determining the risk of bone loss in IBD patients at the time of disease onset. Early identification of patients at high risk of osteoporosis could help to set up more eVective "tailor made" therapy. Our results, together with the recent study in Gastroenterology, 49 suggest that genetic variability may be a major determinant of bone loss in IBD.
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